Abstracts tagged "longitudinal studies"

Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad Rovin¹, Elsa Martins², Cary Austin³, Harini Raghu³, Caleb Chan³, Patrick Chang³, Jay Garg³, Valeria Alberton⁴, Mittermayer Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra Palazuelos⁷, Teresa Baczkowska⁸, José Alfaro⁹, Jorge Ravelo-Hernández¹⁰, Richard Furie¹¹, Luís Pinto¹², Eduardo Albiero¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler², Theodore Omachi³, William Pendergraft III³ and Ana Malvar¹⁶, ¹Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³Genentech, Inc., South San Francisco, California, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C., Mexico City, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clinica San Juan Bautista, Unidad de Investigacion en Reumatologia e Inmunologia, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, Great Neck, New York, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Medellín, Colombia, ¹³Sanatorio Allende, Córdoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, Arkansas, ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁶Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…
Abstract Number: 1695 • ACR Convergence 2025
The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
Ziyuan He¹, Marla Glass¹, Mark Gillespie¹, Elisabeth Dornisch¹, Pravina Venkatesan², Troy Torgerson³, Kevin Deane⁴, Gary Firestein⁵, Adam Savage¹, Xiaojun Li¹, V. Michael Holers⁶, Fan Zhang⁷, David Boyle⁸, Christy Bennett¹, Kristine Kuhn⁹, Kristen Demoruelle¹⁰, Peter Skene¹¹ and Ananda Goldrath¹¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Enumclaw, WA, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵University of California, San Diego, San Diego, CA, ⁶University of Colorado, Denver, CO, ⁷The University of Colorado, Aurora, CO, ⁸UCSD, La Jolla, CA, ⁹²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ¹⁰University of Colorado Anschutz Medical Campus, Golden, CO, ¹¹Allen Institute for Immunology, Seattle
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone destruction. RA is preceded by a subclinical phase defined by elevated…
Abstract Number: 0536 • ACR Convergence 2025
Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Isaac Cheng¹, Ho So¹, Yingzhao jin¹, Vivian Hung², Ling Qin², James Griffith³ and Lai Shan Tam¹, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Bone Quality and Health Centre, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Enthesitis is a hallmark feature of psoriatic arthritis (PsA). Chronic inflammation in the entheses can lead to the formation of enthesiophytes (bony spurs), and…
Abstract Number: 1681 • ACR Convergence 2025
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Belén Serrano-Benavente⁷, Judit Font-Urgelles⁸, Angel Garcia-Aparicio⁹, Sara Manrique-Arija¹⁰, Jesús Alberto Garcia Vadillo¹¹, Ruth Lopez-Gonzalez¹², Javier Narváez¹³, Maria Beatriz Rodriguez¹⁴, Carlos Galisteo¹⁵, Jorge Juan Gonzalez Martin¹⁶, Paloma Vela Casasempere¹⁷, Rabadán Elena¹⁸, Antonio Naranjo¹⁹, Beatriz Paredes-Romero²⁰, Leyre Riancho-Zarrabeitia²¹, Sheila Melchor Diaz²², Irene Altabás-González²³, Sergi Heredia Martin²⁴, Clara Moriano²⁵, Mª Angeles Blazquez Cañamero²⁶, Paula Estrada-Alarcón²⁷, Enrique Judez²⁸, Nerea Alcorta Lorenzo²⁹, Javier Loricera³⁰, Rosalía Martínez Pérez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Hospital Regional Universitario Málaga, Malaga, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Zamora Health Complex, Salamanca, Spain, ¹³Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁵Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁶HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁸Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ¹⁹Hospital Dr Negrin, PALMAS DE GRAN CANARIA (LAS), Spain, ²⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²¹Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²²¹² de Octubre University Hospital, Madrid, Spain, ²³Complejo Hospitalario de Vigo, Vigo, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶Hospital Ramon y Cajal, Madrid, Spain, ²⁷Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁸Albacete University Hospital, Albacete, Spain, ²⁹University Hospital Donostia, san sebastian, Spain, ³⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…
Abstract Number: 0414 • ACR Convergence 2025
Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study
Mariia Pavlenko¹, Mekibib Altaye², Hermine Brunner³, Margaret Chang⁴, Ashley Cooper⁵, Stefanie Davidson⁶, Alexandra Duell³, Bharti Gangwani⁴, Aimee Hersh⁷, Gary Holland⁸, Carl Langefeld⁹, Melissa Lerman¹⁰, Mindy Lo⁴, Virginia Miraldi Utz³, Sampath Prahalad¹¹, Grant Schulert³, Megan Quinlan-Waters¹², Erin Stahl⁵, Edmund Tsui⁸ and Sheila Angeles-Han¹³, ¹Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Children's Mercy Kansas City, Kansas City, MO, ⁶Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT, ⁸UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ⁹Wake Forest University School of Medicine, Winston Salem, NC, ¹⁰Division of Rheumatology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, Philadelphia, PA, ¹¹Emory + Children's Pediatric Institute, Atlanta, GA, ¹²Cincinnati Children's Hospital Medical Center, CCHMC, ¹³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and can lead to vision loss if not detected early. Current clinical…
Abstract Number: 1631 • ACR Convergence 2025
New Arterial Damage in Takayasu’s Arteritis
Tanaz Kermani¹, Sema Kaymaz-Tahra², Aysegul Avcu³, Fatma Alibaz-Oner⁴, Haner Direskeneli³ and Peter Merkel⁵, ¹University of California Los Angeles, Santa Monica, CA, ²Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ³Marmara University, Istanbul, Turkey, ⁴MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Damage is one of the consequences of disease and is often considered irreversible. This study aimed to evaluate new arterial damage in Takayasu’s arteritis…
Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Daniel Lovell¹, Nicolino Ruperto², Jennifer Huggins³, Ekaterina Alexeeva⁴, Colleen Correll⁵, John Bohnsack⁶, Stacey Tarvin⁷, Gabriele Simonini⁸, Thomas Griffin⁹, Andrew Zeft¹⁰, Gerd Horneff¹¹, Pierre Quartier¹², Iionka Orban¹³, Heather Walters¹⁴, Valda Stanevica¹⁵, Julisa Patel¹⁶, Adam M Huber¹⁷, Margalit Rosenkranz¹⁸, Daniel Kingsbury¹⁹, Rosie Scuccimarri²⁰, Gabriel Vega Cornejo²¹, Joost Swart²², Robert Carroll²³, Hermine Brunner¹, Tina Sherrard²⁴, Chiara Pallotti²⁵, Clara Malattia²⁶ and Alberto Martini²⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Università degli Studi Milano-Bicocca, Milan, Italy, ³Cincinnati Children's Medical Center, Cincinnati, OH, ⁴National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Utah, Salt Lake City, UT, ⁷Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁸Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ⁹Atrium Health Levine Children’s Hospital, Charlotte, NC, ¹⁰Cleveland Clinic, Cleveland, OH, ¹¹Asklepios Klinik, Hamburg, Germany, ¹²Hôpital Necker-Enfants Malades, Paris, France, ¹³Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, ¹⁴Northwell, New Hyde Park, NY, ¹⁵Riga Stradiņš University, Riga, Latvia, ¹⁶Children’s Hospital of Georgia, Augusta University, Augusta, GA, ¹⁷IWK Grace Health Centre, Halifax, NS, Canada, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ²⁰McGill University Health Centre, Montreal, QC, Canada, ²¹Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, ²²Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²³Bristol Myers Squibb, London, United Kingdom, ²⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁵Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, ²⁶Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
Abstract Number: 1586 • ACR Convergence 2025
Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Stefano Di Donato¹, Marie-Elise Truchetet², Marco Minerba³, Oliver Distler⁴, JUAN JOSE ALEGRE SANCHO⁵, Yolanda Braun Moscovici⁶, Christina Bergmann⁷, Petros Sfikakis⁸, Jeska de Vries-Bouwstra⁹, Murray Baron¹⁰, Silvia Bellando-Randone¹¹, Lorenzo Dagna¹², Christopher Denton¹³, Madelon Vonk¹⁴, Vanessa Smith¹⁵, Ivan Castellvi¹⁶, Gabriela Riemekasten¹⁷, Andra Balanescu¹⁸, Masataka Kuwana¹⁹, Maria De Santis²⁰, Kamal Solanki²¹, Anastas Batalov²², Vahan Mukuchyan²³, Marco Matucci-Cerinic²⁴, Yannick Allanore²⁵, Francesco Del Galdo²⁶ and Michael Hughes²⁷, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁵Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rambam Heath Care Campus, Haifa, Israel, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Self employed, Montréal, Canada, ¹¹University of Florence, Florence, Florence, Italy, ¹²Ospedale San Raffaele, Milano, Italy, ¹³University College London, UK, London, United Kingdom, ¹⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁷University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁰Humanitas University, Pieve Emanuele, Italy, ²¹Waikato Hospital, Hamilton, New Zealand, ²²Medical University of Plovdiv, Plovdiv, Bulgaria, ²³"Erebuni" Medical Center, Yerevan, Armenia, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Université Paris Cité, Paris, France, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease characterized by vasculopathy, fibrosis, and immune dysregulation. While JAK inhibitors (JAKi) have shown promising immunomodulatory…
Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
RITESH KUMAR MISHRA¹, SUBIN PHILIP², RIZWANA NAUSHAD², AISHWARYA GOPAL³, Chengappa Kavadichanda², CHRISTINA MARIASELVAM², RAJESH N G², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…
Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Amirtha Gopalan¹, keerthi vardhan yerram², Mahesh Gaikwad² and Liza rajasekhar³, ¹Nizams Institute of Medical Sciences, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…
Abstract Number: 0076 • ACR Convergence 2025
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Emma Weis¹, Harlan Sayles¹, Geoffrey Thiele¹, Samir Rachid Zaim², Tony Merriman³, Bryant England¹, Xiaojun Li², LauraKay Moss⁴, Jess Edison⁵, Marie Feser⁴, V. Michael Holers⁶, Kevin Deane⁷, Ted Mikuls¹ and Austin Wheeler¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Allen Institute for Immunology, Seattle, WA, ³University of Alabama at Birmingham, Homewood, AL, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
Abstract Number: 2572 • ACR Convergence 2025
Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Hunter Sporn¹, Roshni Parulekar-Martins¹, Haopeng Wang¹, Xinran Yu¹, Jeong Yee², Youngmin Kim³, Jing Cui⁴ and Karen H. Costenbader⁵, ¹Massachusetts Institute of Technology, Boston, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Timely diagnosis and clinically meaningful stratification of systemic lupus erythematosus (SLE) remain major unmet needs. Existing risk models rely on limited genetic or lifestyle…
Abstract Number: 1289 • ACR Convergence 2025
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Jida Jaffan¹, Tala El Tal², Lawrence Ng³, Asha Jeyanathan⁴, Hunter Hogarth⁵, Adrienne Davis⁴, Linda Hiraki⁵, Deborah Levy⁵, Zahi Touma⁶, Natoshia Cunningham⁷, Ashley Danguecan⁸ and Andrea Knight⁸, ¹The Hospital for Sick Children/ University of Toronto, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Michigan State University, Grand Rapids, MI, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Pain is a common symptom in childhood-onset systemic lupus erythematosus (cSLE) which impacts health-related quality of life. Its relationship to disease measures over time…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…

1
2
3
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].